Insider · CIK 0002082917
James Gordon Liddy
Files at HEPA (Hepion Pharmaceuticals, Inc.), CNTN (Tharimmune, Inc.). First filing -, latest -.
In brief
James Gordon Liddy files SEC Form 4 as director at HEPA (Hepion Pharmaceuticals, Inc.), and also at CNTN (Tharimmune, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James Gordon Liddy has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | HEPA Hepion Pharmaceuticals, Inc. | AGrant or award Stock Optionsderivative | +299,000 | $0.00 | $0 | 299,000 | Aug 21, 2026 |
| Nov 3, 2025 | CNTN Tharimmune, Inc. | AGrant or award Stock Optionderivative | +5,000 | $0.00 | $0 | 55,000 | Nov 5, 2025 |
Questions about James Gordon Liddy
Answered from the filings on this page, as of the latest one.
Is James Gordon Liddy buying or selling?
James Gordon Liddy has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James Gordon Liddy's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Gordon Liddy has 0.
Where does James Gordon Liddy file Form 4?
James Gordon Liddy has filed Form 4 at HEPA (Hepion Pharmaceuticals, Inc.); CNTN (Tharimmune, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.